Focused on the discovery and development of protein-based therapeutics
Amunix Pharmaceuticals is a privately held drug discovery and development company with two proprietary technologies, XTEN® and ProTIA, that enable the rapid generation of protein therapeutics that are engineered to be fit for purpose. In 2018, Frazier acquired a majority stake in Amunix and is committed to building a leading biotechnology company devoted to discovering and developing innovative therapeutics for patients with cancer and other serious diseases. The Amunix platform has been validated through multiple collaborations with leading biopharmaceutical companies, including Celgene, Genentech, Janssen, Roche, Bioverativ, and Baxter.
